<DOC>
	<DOC>NCT00650104</DOC>
	<brief_summary>The purpose of this study is to obtain information on the long-term safety, tolerability, and therapeutic benefit of extended release ropinirole XL, and to provide a mechanism for patients who participated in either Study 167 or Study 164 to continue receiving ropinirole XL if they chose to do so.</brief_summary>
	<brief_title>Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Males or nonpregnant/nonbreast feeding females At least 30 years of age Diagnosis of idiopathic Parkinson''s disease (Hoehn &amp; Yahr criteria) Completed either Study 167 or Study 164 Presence of uncontrolled psychiatric, hematological, renal, hepatic,endocrinological, neurological, cardiovascular disease or active malignancy Dizziness or fainting due to orthostatic hypotension on standing Significant sleep disorder Drug abuse or alcoholism</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>ropinirole IR</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>open-label</keyword>
	<keyword>long term safety; REQUIP</keyword>
	<keyword>ropinirole XL</keyword>
	<keyword>ropinirole CR</keyword>
	<keyword>Parkinson's disease</keyword>
</DOC>